Alexion Signs an Option to Co-Develop and Commercialize Agreement with Stealth for Elamipretide

Alexion’s Ultomiris (ravulizumab) Receives MHLW’s Marketing Authorization for Paroxysmal Nocturnal Hemoglobinuria in Adults


  • Alexion to get exclusive WW rights to develop and commercialize Elamipretide (SC) outside the US with an exclusive option to partner with Stealth for the development of Elamipretide based on P-III results in PMM. Stealth to receive up front $30M, option fee, an equity investment plus development funding
  • If Alexion exercises the option, the companies will jointly co-promote Elamipretide in the US and will co-develop Elamipretide (SC) in the US for PMM, Barth syndrome and Leber’s hereditary optic neuropathy (LHON). Stealth to receive additional option exercise fee, an equity investment, development funding, regulatory & commercial milestone payments
  • Elamipretide is a mitochondria-targeted therapeutic developed for primary mitochondrial myopathy (PMM) currently evaluated in P-III and has also received Fast Track and Orphan Designation for PMM, Barth syndrome and LHON

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: Twitter